Pegfilgrastim Product Approval Information - Licensing Action

Proper name: Pegfilgrastim
Tradename: Neulasta
Manufacturer: Amgen, Inc, Thousand Oaks, CA, License #1080
Indication for Use: To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Approval Date: 1/31/2002
Type of submission: Biologics license application


Label (PDF)

Patient Label (PDF)

Page Last Updated: 04/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.